The discovery of additional GLP-1 signaling pathways (unrelated to glucose lowering effects) is very likely to make this class of medication relevant for the treatment of several chronic diseases, including obesity, T2DM, cardiovascular diseases, cancer, neurodegenerative and neuroinflammatory diseases, and others. The gene discussed is GLP1R; the disease is cardiovascular disorder.